BackLifeMD- 8.875% PRF PERPETUAL USD 25 - Ser A Overview

LifeMD- 8.875% PRF PERPETUAL USD 25 - Ser A Operating Income

LifeMD- 8.875% PRF PERPETUAL USD 25 - Ser A's operating income is $-10M.

Get informed when a big investor buys or sells

+ Follow

Quarterly Operating Income

$-8929072.00
451.13% YoY

As of Mar 31, 2026

Annual Operating Income (TTM)

$-10471799.00
10818.76% YoY

Trailing 12 months ending Mar 31, 2026

Average Operating Income (Comparison Companies)

Operating Income History

Operating Income Comparison

Annual Operating Income Growth Rate (%)

Annual Operating Income Growth (Absolute)

LifeMD- 8.875% PRF PERPETUAL USD 25 - Ser A (LFMDP) FAQ

As of the most recent data (March 2026), LFMDP shows a operating income of $-10M. That compares with $98K in the prior-year period — down 10818.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LFMDP's operating income is now $-10M (was $98K) — a 10818.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether LifeMD- 8.875% PRF PERPETUAL USD 25 - Ser A is outperforming or lagging.

Tracking LFMDP's operating income over time shows whether LifeMD- 8.875% PRF PERPETUAL USD 25 - Ser A is scaling, shrinking, or reshaping that part of the business. The current reading is $-10M That compares with $98K in the prior-year period — down 10818.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has LifeMD- 8.875% PRF PERPETUAL USD 25 - Ser A's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-10M) with ownership activity and broader fundamentals.

LifeMD- 8.875% PRF PERPETUAL USD 25 - Ser A's operating income is $-10M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.